Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Trial of Atezolizumab and Bevacizumab in Combination With CHS-388 (Formerly Known as SRF388) or Placebo in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma.

NCT05359861 is registered in ClinicalTrials.gov with Coherus Oncology, Inc. as lead sponsor.

NCT NCT05359861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05359861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Trial of Atezolizumab and Bevacizumab in Combination With CHS-388 (Formerly Known as SRF388) or Placebo in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma.
Lead sponsor
Coherus Oncology, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
April 12, 2022
Completion date
July 8, 2025
Enrollment
30 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma